Avoid Overbasalization and Clinical Inertia in Patients With Type 2 Diabetes

Activity Preview

The speakers address the overuse of basal insulin in lieu of adding injectable bolus options, known as overbasalization. This is commonly seen in many patients with type 2 diabetes. Additionally, the speakers will discuss how this plays a role within clinical inertia, the lack of intensifying treatment despite not achieving the A1C goal. The discussion will provide the audience with the knowledge of current practice, as well as tools to help play an integral role in healthcare delivery to overcome these challenges.

Learning Objectives

At the completion of this knowledge-based activity, participants will be able to:

  • Define overbasalization and clinical inertia.
  • Discuss the multifactorial reasons for overbasalization and clinical inertia.
  • Discuss the consequences of failing to intensify therapy to patients with type 2 diabetes.  
  • Describe the evidence available regarding utilization of beneficial bolus agents in the management of type 2 diabetes mellitus.

Activity type: Knowledge-based
Target Audience: Pharmacists 
Learning level: 1

Accreditation Information

ACPE Logo

The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The following education course is approved for 1.0 contact hour of CPE credit (0.1 CEU). The ACPE Universal Activity Number for this activity is 0202-0000-21-117-H01-P. 

To obtain credit for completing Avoid Overbasalization and Clinical Inertia in Patients With Type 2 Diabetes,  participants will need to watch the archived webinar, complete the assessment with a grade of 70% or better, complete the evaluation questions, and then CLAIM credit. Participants need to have a valid pharmacist.com username and password to claim credit. After credit has been claimed, please visit CPE monitor for your transcript.

APhA continuing pharmacy education policy provides you with two opportunities to successfully complete this continuing pharmacy education assessment. Please note that you will not be permitted to submit the assessment a third time. The current policy of the APhA Education Department is not to release the correct answers to any of our CPE tests. This policy is intended to maintain the integrity of the CPE activity and the assessment.

Initial release date: February 3, 2021
Expiration date: February 3, 2024 - No credit can be earned after this date

Development

Avoid Overbasalization and Clinical Inertia in Patients With Type 2 Diabetes is an activity for pharmacists developed by the American Pharmacists Association, in collaboration with the APhA-APPM Diabetes Management Special Interest Group. ©2021 American Pharmacists Association

Disclosures

Pooja Patel, PharmD, BCACP, CDCES; Kelsey Buckley, PharmD, BCACP;  and APhA’s editorial staff declare no conflicts of interest or financial interests in any product or service mentioned in this activity, including grants, employment, gifts, stock holdings, and honoraria. For a complete list of APhA staff disclosures, visit the APhA website at www.pharmacist.com/apha-disclosures

Conflicts of interest have been resolved through content review by Helen Sairany, BA, PharmD, MBA, BCACP, Director of Content Development & Partnership at the American Pharmacists Association. 

Fee

There is no fee associated with this activity, available exclusively to current APhA members as a free member benefit. 

System Requirements

Computer and internet access are required to complete this activity.  Please visit our website to view the Technology System Requirements in order to have a positive learning experience.